Noncardiac conditions, such as a blood clot in the lung or hyperthyroidism, may also cause atrial fibrillation. What is the drug of choice for atrial fibrillation? There is no single drug of choice ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

Dignity Health Atrial fibrillation (AFib) is a common heart rhythm disorder that affects millions of people worldwide. By 2030, it is estimated that 12 million Americans will have ...

A rapid heartbeat and shortness of breath could be signs of atrial fibrillation (AFib), an irregular heartbeat. Dr. Jim Stone, a cardiac electrophysiologist at North Medical Center in Tupelo, helps ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

Flossing your teeth at least once a week might lower the risk of stroke caused by blood clots and irregular heartbeats, ...

Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...

If left untreated, Afib can lead to stroke, heart failure and premature cardiac death. But fortunately, Afib is treatable and, in some cases, preventable.

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...